Cargando…

Pathophysiological Underpinnings of Multiple Myeloma Progression

BACKGROUND: Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in the bone marrow. Myeloma is characterized by skeletal destruction, renal failure, hypercalcemia, and anemia. Currently, there is no cure, though recent understanding of the bone marrow microenvironment and t...

Descripción completa

Detalles Bibliográficos
Autor principal:	Jagannath, Sungar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2008
Materias:	Cea
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437616/ https://www.ncbi.nlm.nih.gov/pubmed/18774880 http://dx.doi.org/10.18553/jmcp.2008.14.S7-A.7

Ejemplares similares

Introduction: Multiple Myeloma
por: Cook, Richard
Publicado: (2008)

Current and Emerging Treatments for Multiple Myeloma
por: Schwartz, Rowena N., et al.
Publicado: (2008)

Economic and Clinical Impact of Multiple Myeloma to Managed Care
por: Cook, Richard
Publicado: (2008)

Multiple Myeloma: Supportive Care Requirements and Coordination of Patient-Centered Care
por: Bugos, Kelly G., et al.
Publicado: (2012)

Applying Oncology Formulary and Benefit Design Innovations to the Management of Multiple Myeloma in the Managed Care Setting
por: Mullins, C. Daniel
Publicado: (2012)

The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition
por: Atlas, Steven A.
Publicado: (2007)

Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer
por: Benson, Al
Publicado: (2007)

Multiple Vaccines: How Do We Choose?
por: Minkoff, Neil B.
Publicado: (2007)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies
por: Owens, Gary M., et al.
Publicado: (2013)

Disease Progression and the Application of Evidence-Based Treatment Guidelines Diagnose It Early: A Case for Screening and Appropriate Management
por: Manley, Harold J.
Publicado: (2007)

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
por: Foley, John F., et al.
Publicado: (2013)

Pharmacy Management Strategies for Improving Drug Adherence
por: Fleming, William K.
Publicado: (2008)

Beyond LDL-Cholesterol: The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy
por: Watson, Karol E.
Publicado: (2008)

Managing the Intersection of Medical and Pharmacy Benefits
por: McDonald, Robert C.
Publicado: (2008)

The Impact of Residual Cardiovascular Risk in Combination Lipid-Modifying Therapy in the Managed Care Setting
por: Talbert, Robert L.
Publicado: (2008)

Evolving Issues in the Clinical and Managed Care Settings on the Management of Menopause Following the Women's Health Initiative
por: Lukes, Andrea
Publicado: (2008)

Value-Based Benefit Design: Using a Predictive Modeling Approach to Improve Compliance
por: Mahoney, John J.
Publicado: (2008)

Guidelines and Performance Measures for the Prevention and Treatment of Venous Thromboembolism
por: Fanikos, John
Publicado: (2008)

Benefit Design Innovations to Manage Specialty Pharmaceuticals
por: Stern, Debbie
Publicado: (2008)

The Promise of Specialty Pharmaceuticals: Are They Worth the Price?
por: Sullivan, Sean D.
Publicado: (2008)

Health Plan Approach to Operationalizing a Specialty Drug Management Program
por: Tegenu, Mesfin
Publicado: (2008)

Influencing Patient Adherence to Treatment Guidelines
por: Butterworth, Susan W.
Publicado: (2008)

Management of Acute Coronary Syndrome and Venous Thromboembolism: A Managed Care Perspective
por: Seifert, Randall D.
Publicado: (2008)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

Gender Differences in Health Care Expenditures, Resource Utilization, and Quality of Care
por: Owens, Gary
Publicado: (2008)

Introduction
por: Cziraky, Mark J.
Publicado: (2008)

Not Getting to Goal: The Clinical Costs of Noncompliance
por: Ansell, Benjamin J.
Publicado: (2008)

Guidelines and Performance Measures for the Management of Acute Coronary Syndrome
por: Sobieszczyk, Piotr
Publicado: (2008)

Applying Quality Measures and Guidelines in the Management of Acute Coronary Syndrome and Venous Thromboembolism Introduction
por: Gulseth, Michael P.
Publicado: (2008)

Part1 How the Emergence of Innovative Biologic Agents Impacts Benefit Design, Utilization, and Provider Relations
por: Lipsy, Robert J., et al.
Publicado: (2004)

Introduction
por: Rumsfeld, John S.
Publicado: (2006)

New Treatment Options in COPD
por: Hillman, Daniel E.
Publicado: (2005)

Potential Advantages of Interprofessional Care in Rheumatoid Arthritis
por: Marion, Carrie Engen, et al.
Publicado: (2011)

Practice Strategies to Improve Compliance and Patient Self-Management
por: Ruetsch, Charles
Publicado: (2010)

Implementing the New Guidelines for Hypertension
por: Carter, Barry L.
Publicado: (2004)

COPD Clinical Significance of Early Diagnosis
por: Leff, Richard D.
Publicado: (2005)

Merging P4P and Disease Management: How Do You Know Which One Is Working?
por: Smith, Allen L.
Publicado: (2007)

Epidemiology and Unmet Needs in Hypertension
por: Flack, John M.
Publicado: (2007)

Continuing Education
por: Lipsy, Robert J., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_t4rbivr5ukgnrn9pqbd5h5tulc